Gallo Pasquale, Cecchi Paolo Cipriano, Locatelli Francesca, Rizzo Paolo, Ghimenton Claudio, Gerosa Massimo, Pinna Giampietro
Department of Neurosurgery, University Hospital , Verona , Italy.
Br J Neurosurg. 2013 Dec;27(6):759-64. doi: 10.3109/02688697.2013.776666. Epub 2013 Mar 20.
Pleomorphic Xanthoastrocytoma (PXA) is a rare brain tumour, most commonly affecting children and young adults. To date, only few data regarding the long-term follow-up of these patients after surgery are available. The aim of this study is to describe our single-institution experience in the surgical management of this particular glioma over a period of over 18 years.
We performed a retrospective review of all cases of PXA (40 patients) operated upon at the Department of Neurosurgery of Verona, Italy, between 1990 and 2008. The impact of clinical, radiological, surgical and histological factors on overall survival (OS) and progression-free survival (PFS) was analysed by means of univariate and multivariate models.
We achieved a gross total resection (GTR) in 65% of patients. Histological diagnosis was of grade II in 80%; anaplastic features were present in the remaining 20%. Adjuvant treatment, radiotherapy or chemo-radiotherapy, was administered in 40% of the cases. Median follow-up was 74 months. OS at 5- and 10 years was 76.32% and 68.24%, respectively. PFS at 5- and 10 years was 71% and 58%, respectively. In the multivariate model, histological grade, extent of resection and age at diagnosis (≤ 30 years vs > 30 years) were the only independent prognostic factors for both OS and PFS.
Our retrospective long-term study confirms the relatively favourable prognosis associated with PXA. Young patients with a low-grade tumour (WHO grade II) who underwent GTR carry the longest OS and PFS.
多形性黄色星形细胞瘤(PXA)是一种罕见的脑肿瘤,最常见于儿童和青年。迄今为止,关于这些患者术后长期随访的资料很少。本研究的目的是描述我们单机构在超过18年的时间里对这种特殊胶质瘤进行手术治疗的经验。
我们对1990年至2008年期间在意大利维罗纳神经外科接受手术的所有PXA病例(40例患者)进行了回顾性研究。通过单变量和多变量模型分析临床、放射学、手术和组织学因素对总生存期(OS)和无进展生存期(PFS)的影响。
我们在65%的患者中实现了全切除(GTR)。80%的组织学诊断为二级;其余20%有间变特征。40%的病例接受了辅助治疗,即放疗或放化疗。中位随访时间为74个月。5年和10年的OS分别为76.32%和68.24%。5年和10年的PFS分别为71%和58%。在多变量模型中,组织学分级、切除范围和诊断时年龄(≤30岁与>30岁)是OS和PFS的唯一独立预后因素。
我们的回顾性长期研究证实了PXA相对良好的预后。接受GTR的低级别肿瘤(世界卫生组织二级)的年轻患者的OS和PFS最长。